Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines (Q40066120)

17 September 2017

title

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines (English)

1 reference

17 September 2017

8

David B Weiner

1 reference

17 September 2017

Rong Xu

1

1 reference

17 September 2017

Shakuntala Megati

2

1 reference

17 September 2017

Vidia Roopchand

3

1 reference

17 September 2017

Amara Luckay

4

1 reference

17 September 2017

Amjed Masood

5

1 reference

17 September 2017

Dorys Garcia-Hand

6

1 reference

17 September 2017

Margherita Rosati

7

1 reference

17 September 2017

Barbara K Felber

9

1 reference

17 September 2017

George N Pavlakis

10

1 reference

17 September 2017

Maninder K Sidhu

11

1 reference

17 September 2017

John H Eldridge

12

1 reference

17 September 2017

Michael A Egan

13

1 reference

17 September 2017

language of work or name

English

0 references

publication date

25 July 2008

1 reference

17 September 2017

1 reference

17 September 2017

volume

26

1 reference

17 September 2017

issue

37

1 reference

17 September 2017

page(s)

4819-4829

1 reference

Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

DNA vaccines for viral diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Immunization of animals: from DNA to the dinner plate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Current progress of DNA vaccine studies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Enhancement of DNA vaccine potency in rhesus macaques by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Prime boost vaccines power up in people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Augmenting the immunogenicity of DNA vaccines: role of plasmid-encoded Flt-3 ligand, as a molecular adjuvant in genetic vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

inferred from DOI database lookup

7 January 2021

based on heuristic

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

inferred from DOI database lookup

7 January 2021

based on heuristic

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.06.103

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.06.103

1 reference

17 September 2017

1 reference